Optical Coherence Tomography Artifacts Are Associated With Adaptive Optics Scanning Light Ophthalmoscopy Success in Achromatopsia.
achromatopsia
adaptive optics
inherited retinal disease
optical coherence tomography
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
29
07
2020
accepted:
04
12
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
29
6
2021
Statut:
epublish
Résumé
To determine whether artifacts in optical coherence tomography (OCT) images are associated with the success or failure of adaptive optics scanning light ophthalmoscopy (AOSLO) imaging in subjects with achromatopsia (ACHM). Previously acquired OCT and non-confocal, split-detector AOSLO images from one eye of 66 subjects with genetically confirmed achromatopsia (15 There was excellent agreement between the two observers for assessing OCT artifact severity category (weighted kappa = 0.88). Overall, AOSLO success was 47%. For subjects with OCT artifact severity category 1, AOSLO success was 65%; for category 2, 47%; for category 3, 11%; and for category 4, 0%. There was a significant association between OCT artifact severity category and AOSLO success ( Artifacts in OCT volumes are associated with AOSLO success in ACHM. Subjects with less severe OCT artifacts are more likely to be good candidates for AOSLO imaging, whereas AOSLO was successful in only 7% of subjects with category 3 or 4 OCT artifacts. These results may be useful in guiding patient selection for AOSLO imaging. Using OCT to prescreen patients could be a valuable tool for clinical trials that utilize AOSLO to reduce costs and decrease patient testing burden.
Identifiants
pubmed: 33510950
doi: 10.1167/tvst.10.1.11
pii: TVST-20-2893
pmc: PMC7804582
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Subventions
Organisme : NEI NIH HHS
ID : R01 EY017607
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM080202
Pays : United States
Informations de copyright
Copyright 2021 The Authors.
Déclaration de conflit d'intérêts
Disclosure: K.M. Litts, None; E.N. Woertz, None; M. Georgiou, MeiraGTx (C); E.J. Patterson, None; B.L. Lam, AGTC (F), G.A. Fishman, AGTC (F); M.E. Pennesi, AGTC (F); C.N. Kay, AGTC (F); W.W. Hauswirth, AGTC (I, R); M. Michaelides, MeiraGTx (C); J. Carroll, MeiraGTx (C, F), OptoVue (F), AGTC (F), Translational Imaging Innovations (I)
Références
Graefes Arch Clin Exp Ophthalmol. 1994 Jul;232(7):392-401
pubmed: 7926869
Ophthalmology. 2014 Jan;121(1):234-245
pubmed: 24148654
Retina. 2017 Oct;37(10):1956-1966
pubmed: 28145975
Br J Ophthalmol. 2004 Feb;88(2):291-7
pubmed: 14736794
J AAPOS. 2020 Apr;24(2):82.e1-82.e7
pubmed: 32151571
Invest Ophthalmol Vis Sci. 2014 Aug 07;55(9):5733-43
pubmed: 25103266
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5735-5744
pubmed: 30513534
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1609-14
pubmed: 18385081
Biomed Opt Express. 2011 Aug 1;2(8):2403-16
pubmed: 21833377
Curr Eye Res. 2020 Oct;45(10):1257-1264
pubmed: 32108519
Biomed Opt Express. 2015 Jun 12;6(7):2412-23
pubmed: 26203370
Biomed Opt Express. 2011 Jun 1;2(6):1757-68
pubmed: 21698035
Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2133-41
pubmed: 22427567
Vision Res. 2017 Mar;132:3-33
pubmed: 28212982
Invest Ophthalmol Vis Sci. 2014 Oct 02;55(11):7303-11
pubmed: 25277229
Invest Ophthalmol Vis Sci. 2014 Jun 06;55(7):4244-51
pubmed: 24906859
Invest Ophthalmol Vis Sci. 2019 Dec 2;60(15):5112-5123
pubmed: 31826238
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2631-2640
pubmed: 31237654
Adv Exp Med Biol. 2016;854:277-83
pubmed: 26427422
Shanghai Arch Psychiatry. 2015 Feb 25;27(1):62-7
pubmed: 25852260
Ophthalmology. 2010 Jun;117(6):1177-1189.e4
pubmed: 20171740
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):383-396
pubmed: 30682209
Invest Ophthalmol Vis Sci. 2014 May 20;55(7):4186-98
pubmed: 24845642
Acta Ophthalmol. 2018 Feb;96(1):e54-e58
pubmed: 28391646
Biomed Opt Express. 2012 Nov 1;3(11):2733-51
pubmed: 23162712
Br J Ophthalmol. 2006 Oct;90(10):1259-62
pubmed: 16980644
Biomed Opt Express. 2012 Jun 1;3(6):1182-99
pubmed: 22741067
Transl Vis Sci Technol. 2019 Oct 2;8(5):21
pubmed: 31602346
PLoS One. 2017 Mar 3;12(3):e0169358
pubmed: 28257458
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):40
pubmed: 32203983
J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1313-26
pubmed: 17429477
Transl Vis Sci Technol. 2020 Jun 26;9(7):37
pubmed: 32832242
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95
pubmed: 27479814
Med Image Anal. 2017 Apr;37:129-145
pubmed: 28208100
Opt Express. 2011 Jul 18;19(15):14160-71
pubmed: 21934779
Br J Ophthalmol. 2018 Aug;102(8):1028-1035
pubmed: 29141905